[18F]RP-115 PET/MRI for Alzheimer Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
China Basin, UCSF, San Francisco, CA
Alzheimer Disease
[18F]RP-115 PET/MRI - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This is a first in human study that will assess the safety and diagnostic performance of [18F]RP-115 (fluorine-18 labeled RP115), a positron emission tomography (PET) agent. This agent has the potential to identify the early changes that occur in the brains of patients with Alzheimer disease.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

3 Primary · 1 Secondary · Reporting Duration: A year

A year
Biodistribution of [18F]RP-115
Dosimetry of [18F]RP-115
Safety of Administered dose
Three years
[18F]RP-115 diagnostic performance

Trial Safety

Safety Progress

1 of 3

Trial Design

3 Treatment Groups

Cohort 1 - dosimetry of [18F]RP-115 in healthy volunteers
1 of 3
Cohort 2 - [18F]RP-115 in patients with Alzheimer disease
1 of 3
Cohort 2 - [18F]RP-115 in age-matched controls
1 of 3
Experimental Treatment

68 Total Participants · 3 Treatment Groups

Primary Treatment: [18F]RP-115 PET/MRI · No Placebo Group · Phase < 1

Cohort 1 - dosimetry of [18F]RP-115 in healthy volunteers
Drug
Experimental Group · 1 Intervention: [18F]RP-115 PET/MRI · Intervention Types: Drug
Cohort 2 - [18F]RP-115 in patients with Alzheimer disease
Drug
Experimental Group · 1 Intervention: [18F]RP-115 PET/MRI · Intervention Types: Drug
Cohort 2 - [18F]RP-115 in age-matched controls
Drug
Experimental Group · 1 Intervention: [18F]RP-115 PET/MRI · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: a year
Closest Location: China Basin, UCSF · San Francisco, CA
Photo of San Francisco 1Photo of San Francisco 2Photo of San Francisco 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Alzheimer Disease
0 CompletedClinical Trials

Who is running the clinical trial?

Rio pharmaceuticals Inc.UNKNOWN
David WilsonLead Sponsor
David Wilson, MD, PhDPrincipal InvestigatorUniversity of California, San Francisco

Eligibility Criteria

Age 18+ · All Participants · 9 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are able to provide written informed consent
You have a suitable artery for catheterization.
You are not a smoker, and you are not taking over the counter nicotine cessation.
You are not taking any central nervous system prescription drugs for three weeks.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References